Particulate Matter Testing
Testing for visible and sub-visible particles in injectable pharmaceutical products. Particulates can arise from peptide aggregation, container interactions, or manufacturing contamination. Pharmacopoeial limits for particulate matter apply to all injectable peptide products.
Technical Context
USP <788> / Ph. Eur. 2.9.19 methods: light obscuration (automated particle counter — quantitative, measures particles ≥10μm and ≥25μm in injectable solutions) and membrane microscopy (visual counting on membrane filter — confirmatory method and primary method for low-volume products). Specifications for small-volume injectables (≤100mL): ≤6000 particles ≥10μm per container, ≤600 particles ≥25μm per container. Visible particle inspection: 100% of containers visually inspected against black and white backgrounds under standardised lighting. For peptide drugs, particulate sources include: protein aggregation (the most peptide-specific concern — aggregated peptides form sub-visible and visible particles), glass delamination (from vial inner surface), silicone oil droplets (from syringe lubrication), fibre contamination (from environment), and precipitated excipients. Aggregated peptide particles are particularly concerning because they can be immunogenic.